Lantern Pharma Inc. (LTRN) stock
LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.36−0.02 (-6.17%)
Close on Nov 17, 2026Market cap $4.67MP/E –Yield –
Lantern Pharma total assets
Total assets on the balance sheet at the end of each period.
Lantern Pharma's total assets was $8.52M at Sep 30, 2026. For fiscal 2025 it was $11.04M, down 56.8% from the year before. The highest annual figure on record is $73.95M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.04M | -56.8% |
| FY2024 | Dec 31, 2024 | $25.57M | -41.4% |
| FY2023 | Dec 31, 2023 | $43.65M | -25.8% |
| FY2022 | Dec 31, 2022 | $58.84M | -20.4% |
| FY2021 | Dec 31, 2021 | $73.95M | +263.2% |
| FY2020 | Dec 31, 2020 | $20.36M | +1321.2% |
| FY2019 | Dec 31, 2019 | $1.43M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $8.52M | -37.4% |
| Q2 FY2026 | Jun 30, 2026 | $8.60M | -50.6% |
| Q1 FY2026 | Mar 31, 2026 | $7.22M | -65.8% |
| Q4 FY2025 | Dec 31, 2025 | $11.04M | -56.8% |
| Q3 FY2025 | Sep 30, 2025 | $13.63M | -55.0% |
| Q2 FY2025 | Jun 30, 2025 | $17.42M | -51.0% |
| Q1 FY2025 | Mar 31, 2025 | $21.10M | -46.9% |
| Q4 FY2024 | Dec 31, 2024 | $25.57M | -41.4% |
| Q3 FY2024 | Sep 30, 2024 | $30.29M | -36.6% |
| Q2 FY2024 | Jun 30, 2024 | $35.59M | -30.8% |
| Q1 FY2024 | Mar 31, 2024 | $39.73M | -28.4% |
| Q4 FY2023 | Dec 31, 2023 | $43.65M | -25.8% |
| Q3 FY2023 | Sep 30, 2023 | $47.77M | -23.2% |
| Q2 FY2023 | Jun 30, 2023 | $51.43M | -22.5% |
| Q1 FY2023 | Mar 31, 2023 | $55.51M | -18.8% |
| Q4 FY2022 | Dec 31, 2022 | $58.84M | -20.4% |
| Q3 FY2022 | Sep 30, 2022 | $62.16M | -19.9% |
| Q2 FY2022 | Jun 30, 2022 | $66.38M | -19.5% |
| Q1 FY2022 | Mar 31, 2022 | $68.40M | -17.1% |
| Q4 FY2021 | Dec 31, 2021 | $73.95M | +263.2% |
| Q3 FY2021 | Sep 30, 2021 | $77.61M | +245.0% |
| Q2 FY2021 | Jun 30, 2021 | $82.43M | +221.8% |
| Q1 FY2021 | Mar 31, 2021 | $82.50M | +5659.2% |
| Q4 FY2020 | Dec 31, 2020 | $20.36M | – |
| Q3 FY2020 | Sep 30, 2020 | $22.49M | – |
| Q2 FY2020 | Jun 30, 2020 | $25.61M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.43M | – |
See a number that looks wrong?